arrow
J

Jiwon Oh

University of Toronto
H指数:46
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Challenges and future directions for multiple sclerosis after the 2024 McDonald diagnostic criteria

2024年麦唐纳诊断标准后多发性硬化的挑战与未来方向

2026-07-090
PRE
Cerebellar magnetization transfer ratio and its relationship to clinical outcomes in radiologically isolated syndrome and multiple sclerosis

小脑磁化传递比及其与放射孤立综合征和多发性硬化临床结局的关系

2026-06-230
PRE
Generalizable spinal cord multiple sclerosis lesion segmentation across MRI contrasts, protocols, and centers

MRI对比度、协议和中心间可泛化的脊髓多发性硬化病灶分割

2026-04-240
PRE
Diagnostic performance of central vein sign and paramagnetic rim lesion integration for multiple sclerosis

中央静脉征和顺磁性边缘病灶整合对多发性硬化的诊断性能

2026-04-200
PRE
Insights into adherence to cladribine tablets in the real world in multiple countries: results from patient support programs

多国真实世界中克拉屈滨片剂依从性的见解:来自患者支持项目的结果

2026-03-280
PRE
A cross-sectional study investigating age of multiple sclerosis onset and its association with self-management knowledge and behaviors

一项横断面研究,探讨多发性硬化症发病年龄及其与自我管理知识和行为的关系。

2025-10-270
PRE
Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria

多发性硬化症的诊断:2024年麦卡唐纳标准的修订

2025-09-170
OA
2024 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosis

2024年MAGNIMS–CMSC–NAIMS关于MRI在多发性硬化症诊断中应用的共识建议

2025-09-170
PRE
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis

造血干细胞移植与免疫重建疗法在复发型多发性硬化中的比较

Brain
IF11.7
2025-08-040
PRE
Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study

芬奈布鲁替尼在复发型多发性硬化中的安全性和有效性(FENopta):一项多中心、双盲、随机、安慰剂对照、Ⅱ期试验及开放标签扩展研究

2025-07-160
PRE
Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024)

四年之后:MSBase妊娠、新生儿结局及女性健康登记册(2020–2024)中报告的妊娠与分娩结局

2025-07-070
PRE